Familial Hypercholesterolaemia: consultation (8th February 2008)
A clinical practice guideline on Familial Hypercholesterolaemia is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations. Closing date for comments is 7th April 2008.
Click here for Full Guideline
Click here for Nice Guideline
Click here for Appendix A
Click here for Appendix B
Click here for Appendix C
Click here for Appendix D
Click here for Appendix E
Click here for Appendix F
Click here for Appendix G
Click here for Comments proforma
Lung cancer (non-small cell) – erlotinib (appraisal consultation) (11th February 2008)
The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a single technology appraisal (STA) of erlotinib and provide guidance on its use to the NHS in England and Wales. The Appraisal Committee has held its third meeting to consider the evidence submitted by the manufacturer and the views and evidence put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of erlotinib. Closing date for 3rd March 2008.
Click here for Consultation
Click here for Evaluation Report
Lipid modification: Consultation on section 4.3 – Cardiovascular risk assessment (11th February 2008)
A clinical practice guideline on lipid modification is being developed for use in the NHS in England and Wales. Registered stakeholders for the lipid modification guideline are invited to comment on section 4.3 of the full guideline relating to cardiovascular risk assessment, via this website. Closing date for comments is 7th March 2008.
Click here for Section 4.3
Click here for Comments proforma
Head and neck cancer – cetuximab (appraisal consultation) (11th February 2008)
The Department of Health and the Welsh Assembly Government have asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a single technology appraisal (STA) of cetuximab and provide guidance on its use to the NHS in England and Wales. The Appraisal Committee has met to consider both the evidence submitted by the manufacturer and the views and evidence put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of cetuximab. Closing date for comments is 4th March 2008.
Click here for Consultation
Click here for Evaluation Report
A clinical practice guideline on Familial Hypercholesterolaemia is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations. Closing date for comments is 7th April 2008.
Click here for Full Guideline
Click here for Nice Guideline
Click here for Appendix A
Click here for Appendix B
Click here for Appendix C
Click here for Appendix D
Click here for Appendix E
Click here for Appendix F
Click here for Appendix G
Click here for Comments proforma
Lung cancer (non-small cell) – erlotinib (appraisal consultation) (11th February 2008)
The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a single technology appraisal (STA) of erlotinib and provide guidance on its use to the NHS in England and Wales. The Appraisal Committee has held its third meeting to consider the evidence submitted by the manufacturer and the views and evidence put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of erlotinib. Closing date for 3rd March 2008.
Click here for Consultation
Click here for Evaluation Report
Lipid modification: Consultation on section 4.3 – Cardiovascular risk assessment (11th February 2008)
A clinical practice guideline on lipid modification is being developed for use in the NHS in England and Wales. Registered stakeholders for the lipid modification guideline are invited to comment on section 4.3 of the full guideline relating to cardiovascular risk assessment, via this website. Closing date for comments is 7th March 2008.
Click here for Section 4.3
Click here for Comments proforma
Head and neck cancer – cetuximab (appraisal consultation) (11th February 2008)
The Department of Health and the Welsh Assembly Government have asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a single technology appraisal (STA) of cetuximab and provide guidance on its use to the NHS in England and Wales. The Appraisal Committee has met to consider both the evidence submitted by the manufacturer and the views and evidence put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of cetuximab. Closing date for comments is 4th March 2008.
Click here for Consultation
Click here for Evaluation Report
No comments:
Post a Comment